Clinical Trials on BCR-ABL1-Negative Myeloid Neoplasms in United Kingdom

Total 5124 results

SCRI Development Innovations, LLC

Terminated

SCRI Tissue Testing Registry

Melanoma | Lymphoma | Multiple Myeloma | Myelodysplastic Syndrome

United States
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Lymphoma | Multiple Myeloma

United States, Belgium, France, Germany, Italy, Japan, United Kingdom, Australia, Poland, Puerto Rico, Canada, Denmark, Hungary, Israel, Spain, Czechia, Ireland, Austria, Switzerland, Greece, Turkey, Romania, United Arab Emirates
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Terminated

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Leukemia | Myeloma | Myeloproliferative Diseases

United States
Cellerant Therapeutics
Department of Health and Human Services

Completed

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
David Rizzieri, MD

Completed

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Leukemia | Myelodysplasia | Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
Duke University

Completed

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

Lymphoma | Leukemia | Myelofibrosis | Solid Tumors | Myelodysplasia | Myeloma | Hodgkin's Disease

United States
University of Rochester

Completed

URMC Related Haplo-identical Donor BMT (HaploOnly)

Lymphoma | Multiple Myeloma | Myelofibrosis | Solid Tumors | Hematological Disease | Immune Deficiencies

United States
The University of Texas Health Science Center at...
South Texas Veterans Health Care System

Completed

Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation

Multiple Myeloma | Mucositis

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Celgene
Amalgam Rx

Terminated

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM (MyHOPE™)

Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Multiple Myeloma | B-Cell Non-Hodgkin Lymphoma

United States
Tufts Medical Center

Terminated

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Lymphoma | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States
Case Comprehensive Cancer Center

Completed

Music Therapy on Nausea and Pain for Autologous Stem Cell

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, France, China, Japan, Germany
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Diarrhea | Multiple Myeloma

United States
Celgene

Active, not recruiting

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Germany, Italy, Spain, Sweden, Japan
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Multiple Myeloma

United States, Spain, Canada
Duke University

Completed

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

Leukemia | Myelodysplasia | Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
Celularity Incorporated

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemorrhagic Disorders | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Antineoplastic Agents | Physiological... and other conditions

United States
Pfizer

Recruiting

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Multiple Myeloma

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Poland, Greece, Australia, Sweden
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Spain, Canada, Finland, Argentina, Norway
AbbVie

Active, not recruiting

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Germany, Italy, Japan, Spain
Pfizer

Completed

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States
Celgene

Completed

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, Canada, Germany, Spain, Denmark, Netherlands, Finland, Italy
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
Pfizer

Recruiting

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

Multiple Myeloma

China, Korea, Republic of, Taiwan, United States, France, Sweden, Australia, Japan, Spain, Czechia, United Kingdom, Canada, Germany, New Zealand, Italy, Poland, Netherlands, Austria, Mexico, Finland, Argentina, Belgium, Brazil, Greece, ... and more
Divaya Bhutani
Genzyme, a Sanofi Company

Recruiting

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma | Non-Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

United States
Northside Hospital, Inc.
Millennium Pharmaceuticals, Inc.

Completed

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

Multiple Myeloma | Acute Leukemia | Myelodysplastic Syndrome | Lymphomas | Chronic Leukemia

United States
Massachusetts General Hospital
The Leukemia and Lymphoma Society

Completed

Meloxicam vs Placebo for Mobilization

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Hematopoietic Stem Cells

United States
NYU Langone Health

Completed

Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions

Multiple Myeloma | Osteoporosis | Disease of the Marrow

United States
University of Michigan Rogel Cancer Center
Genzyme, a Sanofi Company

Completed

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Leukemia | Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome

United States
Pharmacyclics LLC.

Completed

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Lymphoma | Leukemia | Multiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Lymphocytic

United States
Amgen

Completed

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Multiple Myeloma

United States, Canada
Memorial Sloan Kettering Cancer Center
Amgen

Completed

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | HDT-AHCT

United States
Multiple Myeloma Research Foundation

Active, not recruiting

MMRF Molecular Profiling Protocol

Multiple Myeloma | Plasma Malignancy

United States, Canada
Amgen

Completed

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Multiple Myeloma | Solid Tumors

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
Taiho Oncology, Inc.

Terminated

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Multiple Myeloma | NonHodgkin Lymphoma

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

Multiple Myeloma

United States, Italy, Spain, Australia, Belgium, Israel, Germany, France
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); National Marrow Donor Program; Blood and Marrow...

Completed

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Multiple Myeloma

United States
Amgen

Completed

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma

United States
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Multiple Myeloma

United States, Germany
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more

Clinical Trials on BCR-ABL1-Negative Myeloid Neoplasms in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations